Stories
Sun Pharma Secures Global Licensing Deal for Bad Cholesterol Drug Lerodalcibep
- •Sun Pharma has entered into a global licensing, commercialization, and manufacturing agreement with LIB Therapeutics for lerodalcibep, a drug for treating bad cholesterol.
- •The agreement grants Sun Pharma exclusive rights to commercialize and manufacture lerodalcibep worldwide, excluding the US and China.
- •Lerodalcibep (Lyrokaul in EU, Lerochol in US) is a once-monthly PCSK9 inhibitor designed to significantly reduce low-density lipoprotein cholesterol (LDL-C).
- •This partnership strengthens Sun Pharma's innovative medicines portfolio, targeting a $3.7 billion PCSK9 market outside the US and China, growing at a 38% CAGR.
- •LIB Therapeutics will receive upfront and future milestone payments, along with royalties based on net sales in the licensed territories.
Key Questions Answered
Sun Pharma entered into an agreement with LIB Therapeutics to obtain exclusive rights for the commercialization and manufacture of the bad cholesterol treatment drug lerodalcibep worldwide, excluding the US and China. LIB will receive upfront and milestone payments along with royalties based on net sales in those territories.
Lerodalcibep is approved in the European Union under the brand name Lyrokaul for treating adult patients with hypercholesterolaemia and mixed dyslipidaemia, following its approval on September 21, 2026. In the United States, it is approved under the brand name Lerochol to help reduce low-density lipoprotein cholesterol in adults as an adjunct to diet and exercise.
Lerodalcibep is a once-monthly 300 mg/1.2 ml subcutaneous injection that delivers sustained reductions in low-density lipoprotein cholesterol by inhibiting PCSK9. This partnership allows Sun Pharma to access a $3.7 billion PCSK9 market outside the US and China, which has been growing at a 38% compound annual growth rate.
